RWM
ABUS icon

Rialto Wealth Management’s Arbutus Biopharma ABUS Stock Holding History

Rialto Wealth Management’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$557 Buy
+116
New +$509 ﹤0.01% 1638

Other funds holding ABUS

TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
WCM
Whitefort Capital Management New York $406M AUM 84.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Rialto Wealth Management's ABUS Position: Q2 2026 in Review

Rialto Wealth Management opened a new position in Arbutus Biopharma (ABUS) in Q2 2026: 116 shares worth $557. The stake represents ﹤0.01% of the portfolio and ranks #1638 among its holdings.

177 funds tracked by Wall St. Rank hold ABUS as of Q2 2026.

  • Rialto Wealth Management held 116 shares of Arbutus Biopharma worth $557 as of Q2 2026.
  • Arbutus Biopharma was a new Rialto Wealth Management position in Q2 2026.
  • Arbutus Biopharma made up ﹤0.01% of Rialto Wealth Management's portfolio in Q2 2026, its #1638 holding.
  • 177 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2026.

Based on Rialto Wealth Management's 13F filing for Q2 2026, filed 11 Aug 2026.